Department of Otorhinolaryngology, Head and Neck Surgery, Kitasato University School of Medicine, Sagamihara, Japan;
Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
Anticancer Res. 2022 Jun;42(6):3177-3183. doi: 10.21873/anticanres.15807.
BACKGROUND/AIM: In patients with squamous cell carcinoma of the head and neck (SCCHN), delayed surgery can result in poorer postoperative function and prognosis due to the growth of the tumor and extended surgery. Further, delay may even make the tumor unresectable. To prevent tumor growth during the waiting period before surgery, S-1 has been administrated preoperatively at several facilities in Japan. To date, however, the safety and efficacy of preoperative S-1 remain unclear.
We conducted a retrospective cohort study of 118 patients with SCCHN treated with S-1 before radical surgery at 2 institutions in Japan. We evaluated the safety of S-1 therapy, which was evaluated by the incidence of grade 3 or greater adverse events (AEs). The rate of achievement of non-growth of tumors was also calculated.
Regarding safety, 125 AEs of all grades were recorded in 71 patients (60%). Of these, grade 3 AEs were detected in 3 patients (3%), and no grade 4 or 5 AEs occurred. The nongrowth rate of primary lesions and lymph node metastases was 89% and 85%, respectively.
Preoperative S-1 therapy might be useful, with acceptable toxicity, on an outpatient basis in patients with SCCHN.
背景/目的：在头颈部鳞状细胞癌（SCCHN）患者中，由于肿瘤的生长和手术范围的扩大，延迟手术可能导致术后功能和预后较差。此外，延迟甚至可能使肿瘤无法切除。为了防止手术前等待期间肿瘤生长，日本的几家医疗机构在术前给予 S-1 治疗。然而，迄今为止，术前 S-1 的安全性和疗效仍不清楚。
我们对在日本的 2 家机构接受 S-1 术前根治性手术治疗的 118 例 SCCHN 患者进行了回顾性队列研究。我们通过评估 3 级或更高级别的不良事件（AE）的发生率来评估 S-1 治疗的安全性。还计算了肿瘤非生长的发生率。
关于安全性，71 例患者（60%）记录了 125 例所有级别的 AE。其中，3 例患者（3%）出现 3 级 AE，无 4 级或 5 级 AE。原发灶和淋巴结转移的无生长率分别为 89%和 85%。
术前 S-1 治疗可能是有用的，在门诊基础上对 SCCHN 患者具有可接受的毒性。
